PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Palvella Therapeutics Announces First Patient Dosed in SELVA Phase 3 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations